In-silico approaches to prostate cancer
Prostate cancer is the most frequent male cancer. After radiotherapy treatment, the prostate specific antigen (PSA) is used as a biomarker indicating tumor reccurrence. However, it is not still fully clear how to use PSA data to inform clinical decisions, a field in which mathematical models can be helpful. Also, what are the best therapeutic schedules after recurrences combining available drugs, and what are the optimal use of novel theranostic tools are not clear. Mathematical models may help answering those questions.
